Immunization

Investigators found inconsistencies across subgroups, but the overall efficacy and safety of pneumococcal vaccination was affirmed.

Pharmacists should ensure pneumococcal vaccination strategies are tailored to high-risk individuals, especially those with type 2 diabetes (T2D).

Pediatric flu cases surge, revealing alarming rates of encephalopathy.

Pharmacists should leverage their accessibility to boost immunization rates among individuals undergoing cancer treatment.

Using the United States Vaccine Adverse Event Reporting System database, investigators found that pneumococcal vaccination led to predominantly nonserious adverse events.

Pneumococcal 21-valent conjugate vaccine (PCV21) was found to be immunogenic and safe in individuals living with HIV, providing significant indications of efficacy in immunocompromised patients.

Older adults face heightened risks from RSV due to declining immunity and chronic conditions, making vaccination crucial for prevention and health.

The Advisory Committee on Immunization Practices (ACIP) voted to recommend that COVID-19 vaccines be administered through individual-based decision-making.

A multicenter registry analysis reveals that high-risk cardiovascular patients often miss opportunities to receive pneumococcal and influenza vaccinations, showcasing gaps that could be filled by pharmacists.

The BMJ study highlights that young children vaccinated against influenza in October experience the greatest protection, with lower infection rates than those vaccinated earlier.

Members of the Advisory Committee on Immunization Practices (ACIP) voted to restrict the combined measles, mumps, rubella, and varicella (MMRV) vaccine and hepatitis B vaccine for certain age groups.

Long-term care pharmacists are significant in lessening the vaccine hesitancy hurdle among facility residents.

West Coast states unite to enhance vaccine access and guidance for respiratory viruses, prioritizing public health and safety ahead of the 2025-2026 season.

Travelers face rising infectious disease risks, including measles, chikungunya, chagas disease, and others.

Misinformation is fueling parental fears and a concerning drop in childhood vaccines.

Pharmacists face challenges as recent federal policy changes threaten their expanded roles in vaccination and public health, impacting patient access to care.

Use of educational resources at a gastrointestinal office improved pneumococcal vaccine uptake in patients with celiac disease.

In STRIDE-13, the pneumococcal 21-valent conjugate vaccine (PCV21) induced robust immunogenicity in young, high-risk individuals against invasive pneumococcal disease.

A fatal pediatric measles case in Los Angeles highlights the urgent need for MMR vaccination to protect vulnerable children from severe complications.

The rationale for vaccine-related policy changes is lacking.

Experts forecast a potential resurgence of measles and other vaccine-preventable diseases in the U.S. due to declining vaccination rates.

According to phase 3 trial results, Pfizer-BioNTech’s LP.8.1-adapted COVID-19 vaccine demonstrated significant immune responses in older adults and individuals at high risk for severe COVID-19.

Florida's Surgeon General's plan to eliminate school vaccine mandates raises concerns about measles outbreaks and declining vaccination rates.

The 21-valent pneumococcal conjugate vaccine (PCV21) elicited favorable immunogenicity and safety in infants and toddlers who were coadministered common pediatric vaccines, such as the measles-mumps-rubella vaccine.

Research reveals how aging impacts flu severity in older adults, highlighting the need for enhanced vaccines and new therapeutic strategies.